Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Inclusion criteria: Healthy subject in good health, as determined by a medical history, physical examination including vital signs and clinical laboratory tests: * with a body weight between 45 kg and 95 kg if male, between 40 kg and 85 kg if female, and with a Body Mass Index (BMI) between 18 and 30 kg/m² * classified into one of the 4 groups of metabolizers according to his/her CYP2C19 genotype: * Ultrarapid Metabolizers (UMs, CYP2C19\*1/\*17 and CYP2C19\*17/\*17) * homozygous Extensive Metabolizers (homoEMs, CYP2C19\*1/\*1) * heterozygous Extensive Metabolizers (heteroEMs, CYP2C19\*1/\*2 and CYP2C19\*1/\*3) * Poor Metabolizers (PMs, CYP2C19\*2/\*2 and CYP2C19\*2/\*3) Exclusion criteria: * Evidence of inherited disorder of coagulation/hemostasis functions * Subject smoking more than 10 cigarettes or equivalent per day * Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.